Multi Epitope Peptide Vaccine against Human Parvovirus B19 Using Immuno-Informatics Approaches

Nisreen Osman Mohammed¹, Khoubieb Ali Abd-elrahman² and Yassir A. Almofti^3,

¹Ahfad Center for Science and Technology, Ahfad University for Women, Khartoum, Sudan

²Department of pharmaceutical technology, College of Pharmacy, University of Medical Science and Technology (MUST) Khartoum, Sudan

³Department of Biochemistry and Molecular Biology, College of Veterinary Medicine, University of Bahri, Khartoum, Sudan

Cite this paper:
Nisreen Osman Mohammed, Khoubieb Ali Abd-elrahman and Yassir A. Almofti. Multi Epitope Peptide Vaccine against Human Parvovirus B19 Using Immuno-Informatics Approaches. American Journal of Microbiological Research. 2018; 6(4):140-164. doi: 10.12691/ajmr-6-4-3

Abstract

Introduction: Human parvovirus B19 (B19V) is small non-enveloped, single-stranded DNA virus belong to genus Erythrovirus. B19V can cause erythema infectiosum (fifth disease), oligoarthritis, hydrops fetalis and a plastic crisis in patients with sickle cell anemia. A variety of vaccine strategies have been employed targeting immune responses. However their results were controversy with a limiting in availability of viral antigen. Since B19V replicates predominantly in erythroid progenitor cells of human bone marrow, this makes a peptide-based vaccines a promising strategy for development of vaccine against B19V with less allergenic and reactogenic responses. The aim of the present study was to design an efficient multi-epitope vaccine for human B19 virus using VP1 glycoprotein. Material and method: Thirty six sequences of VP1 glycoprotein were retrieved from NCBI database in December 2017 and aligned to determine the conservancy between the retrieved strains. The IEDB different analysis resources were used to predict epitopes that could act as promising peptides vaccine against parvovirus B19. The predicted epitopes were further assessed for population coverage against the whole world population. Results: The epitopes _214-PEVP_-217, _675-GLHQPPP_-681 and _554-SLRPGPVSQPYH_-565 were found to be the most potential epitopes against B cells. For the T cell three epitopes namely _155-FRYSQLAKL_-163, _302-CTISPIMGY_-310 and _316-YLDFNALNL_-324 showed high affinity to MHC-I alleles. The epitopes (core) _155-FRYSQLAKL_-163, _438-FYVLEHSSF_-446 and _404-WVYFPPQYA_-412 showed high affinity to interact with MHC-II alleles. _155-FRYSQLAKL_-163 and _438-FYVLEHSSF_-446 showed high coverage for whole world population with percentage of 99.73% and 94.85% respectively. Conclusion: This study proposed eight epitopes for B and T cells that could be a powerful multi epitope vaccine against B19V. Particular concern directed towards the epitope _155-FRYSQLAKL_-163 which demonstrated merits by reacting efficiently with both MHC-I and MHC-II alleles. Clinical trial is required to proof the efficacy of these epitopes as promising candidate vaccine against parvovirus B19.

Keywords:
Parvovirus B19 VP1 glycoprotein NCBI IEDB Immunoinformatics

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Young NS, Brown KE. Parvovirus B19. New England Journal of Medicine. 2004; 350(6): 586-97.
[2]	Kerr JR. The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. Journal of clinical pathology. 2016; 69(4): 279-91.
[3]	Servant-Delmas A, Morinet F. Update of the human parvovirus B19 biology. Transfusion Clinique et Biologique. 2016; 23(1): 5-12.
[4]	Suzuki M, Yoto Y, Ishikawa A, Tsutsumi H. Analysis of nucleotide sequences of human parvovirus B19 genome reveals two different modes of evolution, a gradual alteration and a sudden replacement: a retrospective study in Sapporo, Japan, from 1980 to 2008. Journal of virology. 2009; 83(21):10975-80.
[5]	Smith-Whitley K, Zhao H, Hodinka RL, Kwiatkowski J, Cecil R, Cecil T, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004; 103(2): 422-7.
[6]	Gasim GI, Eltayeb R, Elhassan EM, Haggaz AD, Rayis DA, Adam I. Human parvovirus B19 and low hemoglobin levels in pregnant Sudanese women. International Journal of Gynecology & Obstetrics. 2016; 132(3): 318-20.
[7]	de Jong EP, de Haan TR, Kroes AC, Beersma MF, Oepkes D, Walther FJ. Parvovirus B19 infection in pregnancy. Journal of clinical virology. 2006; 36(1): 1-7.
[8]	Letalef M, Vanham G, Boukef K, Yacoub S, Muylle L, Mertens G. Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission. Transfusion science. 1997; 18(4): 523-30.
[9]	Kelly H, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiology and Infection. 2000; 124(03): 449-57.
[10]	Anderson LJ. Role of parvovirus B19 in human disease. The Pediatric infectious disease journal. 1987; 6(8): 711-8.
[11]	Pillay D, Kibbler C, Griffiths P, Hurt S, Patou G. Parvovirus B19 outbreak in a children's ward. The Lancet. 1992; 339(8785): 107-9.
[12]	Serjeant GR, Mason K, Topley J, Serjeant BE, Pattison JR, Jones SE, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. The Lancet. 1981; 318(8247): 595-7.
[13]	Greulich S, Kindermann I, Schumm J, Perne A, Birkmeier S, Grün S, et al. Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy. Clinical Research in Cardiology. 2016; 105(1): 37-52.
[14]	Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(32): 11628-33.
[15]	Bansal GP, Hatfield JA, Dunn FE, Kramer AA, Brady F, Riggin CH, et al. Candidate recombinant vaccine for human B19 parvovirus. Journal of Infectious Diseases. 1993; 167(5): 1034-44.
[16]	Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C. 1. Journal of Infectious Diseases. 2003; 187(4): 675-8.
[17]	Effio CL, Oelmeier SA, Hubbuch J. High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography. Vaccine. 2016; 34(10): 1259-67.
[18]	Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines. 2014;2(3):515-36.
[19]	Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nature reviews Drug discovery. 2007;6(5):404-14.
[20]	Hoshino Y. Peptide-Based Immunotherapeutics and Vaccines 2015.
[21]	Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, et al. Phylogeny. fr: robust phylogenetic analysis for the non-specialist. Nucleic acids research. 2008;36(suppl 2):W465-W9.
[22]	Chevenet F, Brun C, Bañuls A-L, Jacq B, Christen R. TreeDyn: towards dynamic graphics and annotations for analyses of trees. BMC bioinformatics. 2006;7(1):439.
[23]	Hall TA, editor BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic acids symposium series; 1999: [London]: Information Retrieval Ltd., c1979-c2000.
[24]	Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, et al. The immune epitope database (IEDB) 3.0. Nucleic acids research. 2015;43(D1):D405-D12.
[25]	Hasan MA, Hossain M, Alam J. A computational assay to design an epitope-based Peptide vaccine against Saint Louis encephalitis virus. Bioinformatics and Biology insights. 2013;7:347.
[26]	Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome research. 2006;2(1):2.
[27]	Emini EA, Hughes JV, Perlow D, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. Journal of virology. 1985; 55(3):836-9.
[28]	Kolaskar A, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS letters. 1990; 276(1-2): 172-4.
[29]	Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, et al. Immune epitope database analysis resource. Nucleic acids research. 2012:gks438.
[30]	Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. Nucleic acids research. 2008;36(suppl 2):W509-W12.
[31]	Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome research. 2008; 4(1): 2.
[32]	Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008; 4(4): e1000048.
[33]	Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC bioinformatics. 2010; 11(1): 568.
[34]	Bui H-H, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC bioinformatics. 2006; 7(1): 153.
[35]	Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proceedings of the National Academy of Sciences. 1988; 85(15): 5409-13.
[36]	Arnon R, Horwitz RJ. Synthetic peptides as vaccines. Current opinion in immunology. 1992; 4(4): 449-53.
[37]	van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Advanced drug delivery reviews. 2006; 58(8): 916-30.
[38]	Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, Brito LA, et al. Generation of a parvovirus B19 vaccine candidate. Vaccine. 2013; 31(37): 3872-8.
[39]	Corcoran A, Mahon BP, Doyle S. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1. Journal of Infectious Diseases. 2004; 189(10): 1873-80.
[40]	Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert review of vaccines. 2010; 9(2): 157-73.
[41]	Klenerman P, Tolfvenstam T, Price DA, Nixon DF, Broliden K, Oxenius A. T lymphocyte responses against human parvovirus B19: small virus, big response. Pathologie Biologie. 2002; 50(5): 317-25.